Reasons for choosing our testing services
ZHONGXI Testing has obtained inspection qualification certifications from multiple countries and regions worldwide. We possess a senior testing team and advanced testing methods, providing independent, impartial, and professional third-party verification services for global carbon projects.
Internationally recognized authority
Certified by multiple international standards such as CNAS, VCS, and GS, with reports universally applicable worldwide.
Global service capability
Covering 140+ countries and regions, it supports on-site detection and remote verification in multiple languages.
Professional experimental methods
Adopt standard experimental methods to ensure accurate and reliable data.
Protein-Protein Interaction (PPI) Analysis Services: Mapping Interactomes for Drug Discovery & Systems Biology
As an independent third-party analytical service provider, we offer comprehensive protein‑protein interaction (PPI) analysis for understanding molecular mechanisms, validating drug targets, mapping signaling networks, and characterizing therapeutic antibodies. Protein‑protein interactions are central to virtually all biological processes – from signal transduction and gene expression to cell cycle control and immune responses. Dysregulation of PPIs underlies many human diseases, including cancer, neurodegeneration, and infectious diseases. Characterizing the binding partners, interaction strength, and structural details of PPIs provides critical insights for target identification, lead optimization, and rational drug design. Our accredited laboratory follows established protocols and international guidelines using orthogonal technologies: surface plasmon resonance (SPR), biolayer interferometry (BLI), microscale thermophoresis (MST), isothermal titration calorimetry (ITC), co‑immunoprecipitation (co‑IP), pull‑down assays, proximity ligation assay (PLA), cross‑linking mass spectrometry (XL‑MS), and yeast two‑hybrid (Y2H). This article outlines our PPI analysis capabilities – including scope, key test items, and standard methods – to help academic researchers, biotech companies, and pharmaceutical developers decipher the interactome with confidence.
1. Our Testing Scope for Protein‑Protein Interaction Analysis
We cover a wide range of interaction types, sample formats, and affinity/avidity ranges:
By interaction pair / complex type: Antibody‑antigen (mAb to target, biosimilar binding, epitope mapping); Receptor‑ligand (growth factor/receptor, cytokine/receptor, GPCR/agonist, checkpoint receptor/ligand); Enzyme‑inhibitor or enzyme‑substrate (kinase/inhibitor, protease/inhibitor, ubiquitin ligase/substrate); Scaffold / adaptor protein interactions (SH2 domain/phosphopeptide, SH3 domain/proline‑rich peptide, PDZ domain/PDZ‑binding motif); Transcription factor‑cofactor; Viral‑host protein interactions (SARS‑CoV‑2 spike/ACE2, influenza NP/host factor); Multi‑protein complexes (ribosome subunits, proteasome, chromatin remodelers).
By sample source / format: Purified recombinant proteins (full‑length, truncated, tagged, or untagged); Native protein complexes (from cell lysates, immunoprecipitates); Cell lysates (overexpressed or endogenous); Synthetic peptides (linear or cyclic, phosphorylated, acetylated).
By binding strength: High affinity (pM to low nM – antibody‑antigen); Medium affinity (nM to μM – many receptor‑ligand pairs); Low affinity (μM to mM – transient interactions, co‑crystallization screening).
By detection principle / technology: Label‑free biosensors – surface plasmon resonance (SPR), biolayer interferometry (BLI), microscale thermophoresis (MST), isothermal titration calorimetry (ITC); Affinity‑based methods – pull‑down (GST, His, biotin), co‑immunoprecipitation (co‑IP) with Western blot or MS readout; Proximity detection – proximity ligation assay (PLA), FRET / BRET, AlphaLISA; Structural mapping – cross‑linking mass spectrometry (XL‑MS), hydrogen‑deuterium exchange mass spectrometry (HDX‑MS); Genetic methods – yeast two‑hybrid (Y2H), split‑luciferase, NanoBiT; In silico docking (computational) – by arrangement.
By output / resolution: Binary interaction (yes/no) – screening; Binding affinity (KD, ka, kd) – kinetic/equilibrium; Binding thermodynamics (ΔH, ΔS, ΔG, n) – calorimetry; Interaction network (discovery of unknown partners) – pull‑down + MS; Spatial proximity (in situ, subcellular localization) – PLA; Residue‑level binding interface – XL‑MS, HDX‑MS.
By research / application area: Drug discovery – target validation, compound mechanism of action (MoA), off‑target profiling; Antibody development – lead ranking, cross‑reactivity, Fc receptor binding; Biosimilar comparability – demonstrating equivalent binding kinetics to reference product; Cell signaling – mapping pathway crosstalk, identifying novel interactors; Infectious disease – host‑pathogen interaction mapping; Personalized medicine – characterizing patient‑specific mutations that disrupt PPIs.
2. Key Test Items & Measurements We Perform
Our PPI analysis services are organized into five categories: kinetic/affinity characterization, thermodynamic profiling, interaction discovery, proximity mapping, and structural/interface mapping.
2.1 Affinity & Kinetics (KD, ka, kd)
Equilibrium dissociation constant (KD) – The concentration of one partner (at equilibrium) that occupies half the binding sites of the other. Lower KD indicates higher affinity. Measured by SPR, BLI, MST, or ITC.
Kinetic rate constants – Association rate (ka, M⁻¹s⁻¹) describes how fast the complex forms; dissociation rate (kd, s⁻¹) describes complex stability. SPR and BLI are the gold standards for real‑time kinetics. For high‑affinity interactions (KD < 100 pM), extended dissociation phases (>1 hour) provide accurate kd as low as 10⁻⁶ s⁻¹.
Steady‑state affinity (for very fast on‑off rates) – When kinetics cannot be resolved (kd > 10⁻² s⁻¹), we measure binding at equilibrium across a concentration range and fit to a steady‑state model.
Avidity (multivalent binding) – For bivalent antibodies or dimeric receptors, we report avidity (functional affinity) using multivalent binding models.
2.2 Thermodynamic Parameters (ΔH, ΔS, ΔG, n)
Isothermal titration calorimetry (ITC) – Directly measures the heat released or absorbed upon binding, providing ΔH (enthalpy change) and ΔS (entropy change). The binding stoichiometry (n) is obtained from the titration curve. The Gibbs free energy ΔG = ΔH – TΔS = –RT ln (1/KD) is also derived. Thermodynamic profiling helps differentiate binding modes (e.g., hydrogen bonding vs. hydrophobic effect) and predicts temperature dependence of affinity.
Van‘t Hoff analysis – For interactions where ITC is not feasible (low affinity, large sample requirement), we measure KD at multiple temperatures by SPR or MST and derive ΔH and ΔS from the van‘t Hoff plot (ln K vs. 1/T).
2.3 Interaction Discovery (Screening for Unknown Binding Partners)
Pull‑down assay + mass spectrometry – A bait protein (GST‑, His‑, or biotin‑tagged) is immobilized on affinity beads and incubated with cell lysate or purified protein library. Bound proteins are eluted and identified by LC‑MS/MS. We report the list of putative interactors with spectral counts and fold‑enrichment over control. This unbiased approach is ideal for identifying novel interaction partners of a protein of interest.
Co‑immunoprecipitation (co‑IP) + Western blot – For a known candidate, we use an antibody against the bait protein to pull down the complex from cell lysate, followed by Western blot with antibody against the prey. We also offer co‑IP with MS readout (co‑IP‑MS) to discover unknown interactors.
Yeast two‑hybrid (Y2H) – For high‑throughput screening of a library against a bait protein, we use the GAL4‑based Y2H system. Positive colonies are sequenced to identify interacting proteins. Available for both human and model organism libraries.
NanoBiT (Nanoluciferase Binary Technology) – Complement‑based luminescence assay for detecting PPI in live cells. High sensitivity, suitable for monitoring dynamic interactions, compound modulation, and transient interactions.
Proximity ligation assay (PLA) – In situ detection of protein‑protein proximity (within <40 nm) in fixed cells or tissues. Two primary antibodies (raised in different species) bind to the two putative interactors. Species‑specific secondary antibodies conjugated with DNA probes generate a circular DNA template only when the two probes are in close proximity. The signal is amplified and visualized as discrete fluorescent dots. PLA confirms subcellular localization of the interaction and can quantify interaction frequency across conditions.
FRET (Förster resonance energy transfer) / BRET (bioluminescence resonance energy transfer) – Measures molecular proximity in live cells. We offer both custom FRET (with labeled proteins or transfected fusion constructs) and commercial BRET systems. Output: FRET efficiency or BRET ratio, indicating interaction strength and distance.
AlphaLISA / AlphaScreen – Bead‑based homogeneous proximity assay. Donor and acceptor beads come into proximity only when the two proteins interact, generating a luminescent signal. High sensitivity, no wash, suitable for high‑throughput screening of PPI modulators.
2.5 Structural & Interface Mapping
Cross‑linking mass spectrometry (XL‑MS) – Chemical cross‑linking (e.g., DSS, BS³) or photo‑cross‑linking of interacting proteins, followed by proteolytic digestion and LC‑MS/MS identification of cross‑linked peptides. Identifies specific residues that are in close spatial proximity, providing distance restraints for structural modeling. We use pLink‑2 or MeroX software for data analysis, reporting cross‑linked residue pairs with FDR ≤ 1%.
Hydrogen‑deuterium exchange mass spectrometry (HDX‑MS) – Measures the rate of deuterium incorporation into the protein backbone. Upon binding, buried interface regions show reduced exchange (protection). We perform HDX‑MS on the free protein and the protein‑protein complex to map the binding interface at near‑residue resolution.
Alanine scanning mutagenesis + binding assay – For structure‑guided validation, we mutate predicted interface residues to alanine and measure the effect on binding affinity (by SPR or MST). A significant loss (>5‑fold increase in KD) indicates a critical residue.
3. Standard Test Methods We Apply
All assays are performed according to established protocols and, where applicable, ICH/FDA guidelines. Our laboratory is ISO/IEC 17025 accredited for SPR/BLI/MST/ITC and follows GMP principles for biosimilar comparability studies.
3.1 Surface Plasmon Resonance (SPR – Biacore)
Method: Ligand immobilization (amine coupling, Ni‑NTA capture, biotin‑streptavidin). Analytic injection (3‑8 concentrations). Double referencing. Global fitting to 1:1 binding model, two‑state model, or heterogeneous analyte model as appropriate. Regeneration conditions (e.g., glycine pH 2.0, MgCl₂) are optimized to preserve ligand activity. For antibody‑antigen interactions, we typically use antigen on chip and antibody as analyte (or vice versa).
3.2 Biolayer Interferometry (BLI – Octet)
Method: Streptavidin (SA) or Ni‑NTA biosensors loaded with biotinylated or His‑tagged protein. Dip into analyte solutions (96‑ or 384‑well plate). Association and dissociation steps. Data reference‑subtracted and globally fit. High throughput, no microfluidics.
3.3 Microscale Thermophoresis (MST)
Method: Fluorescently label one protein (e.g., RED‑NHS dye). Prepare a 16‑step dilution series of the unlabeled partner. Mix equal volumes, incubate, load into capillaries. Measure thermophoretic movement (temperature jump from 25°C to 35°C). KD from dose‑response curve. Works in complex solutions (serum, lysate).
3.4 Isothermal Titration Calorimetry (ITC)
Method: Protein (20‑100 μM) in the cell, ligand (200‑1000 μM) in syringe. 19‑25 injections. Data integration and fitting to one‑site binding model (Origin). Reports KD, ΔH, ΔS, n.
3.5 Co‑IP & Pull‑down + Western / MS
Co‑IP: Cell lysate incubated with antibody against bait protein; Protein A/G beads; washes; elution; SDS‑PAGE; Western blot for prey. For MS, eluted proteins are reduced, alkylated, digested, and analyzed by LC‑MS/MS.
Pull‑down: GST‑, His‑, or biotin‑tagged bait immobilized on beads; incubate with lysate; washes; elution; Western or MS.
3.6 Proximity Ligation Assay (PLA)
Method: Cells or tissues fixed, permeabilized, blocked. Primary antibodies (rabbit against protein A, mouse against protein B). PLA secondary probes (anti‑rabbit PLUS, anti‑mouse MINUS). Ligation and amplification. Fluorescence microscopy. Quantification of PLA dots per cell using image analysis (CellProfiler).
3.7 Cross‑linking Mass Spectrometry (XL‑MS)
Method: Purified protein complex (or cell lysate) cross‑linked with DSS or BS³. Quench, digest (trypsin), enrich cross‑linked peptides (optional), LC‑MS/MS (Orbitrap Fusion Lumos). Identify cross‑links with pLink‑2 or MeroX. FDR ≤ 1% at the unique residue pair level.
4. Why Choose Our Third‑Party Protein‑Protein Interaction Analysis Services?
As an independent laboratory, we provide unbiased, accurate, and publication‑ready data. Our strengths include:
ISO/IEC 17025 accreditation – Our core platforms (SPR, BLI, MST, ITC, LC‑MS) are CNAS/CMA accredited, with results accepted for IND, BLA, and regulatory submissions.
Multi‑technology cross‑validation – For critical interactions, we cross‑validate using orthogonal methods (e.g., SPR + MST, or ITC + BLI) to ensure confidence.
Low sample consumption – SPR requires 10‑30 μg protein; BLI 2‑5 μg; MST 1‑2 μg; ITC 100‑200 μg. Pull‑down/MS requires as few as 1 mg lysate.
Wide affinity range – From pM (high‑affinity antibodies) to mM (weak fragments) across our platforms.
Fast turnaround – Single interaction KD by SPR/BLI within 1‑2 weeks; ITC within 2‑3 weeks; pull‑down + MS identification within 3‑4 weeks; PLA within 2‑3 weeks; XL‑MS within 4‑6 weeks.
Comprehensive reporting – Sensorgrams (raw and fitted), curves, fitted parameters, residuals, thermograms (ITC), cross‑link tables, PLA images with quantification, statistical significance (p‑values).
Confidentiality – Full protection of protein sequences, constructs, and proprietary data.
Consultative support – Our biochemists and structural biologists assist with experiment design (tag choice, buffer optimization, cross‑linker selection), model selection, and interpretation of complex binding behaviors (cooperativity, avidity, non‑1:1 stoichiometry).
Whether you need to characterize a therapeutic antibody’s binding kinetics, discover novel interactors of a signaling protein, map the binding interface of a viral‑host interaction, or validate a small molecule‘s effect on a PPI, our protein‑protein interaction analysis experts are ready to deliver reliable, actionable results.
Get Started with Your PPI Analysis Project
Contact our team with your protein information (source, tags, purity), interaction pair(s), desired parameters (KD, kinetics, thermodynamics, interactors, interface), and any special requirements (buffer conditions, temperature, multi‑complex). We will provide a detailed quotation, sample submission guidelines, and a testing schedule. Let us help you map the interactome with precision and confidence.
This article provides an overview of our protein‑protein interaction analysis capabilities. For specific methods, sample quantity, and pricing, please request a tailored service proposal.